Saltar al contenido
Merck
Todas las fotos(1)

Documentos

487R-9

SMAD4 (MRQ-72) Rabbit Monoclonal Antibody

For In Vitro Diagnostic Use in Select Regions

Sinónimos:

Mothers Against Decapentaplegic Homolog 4 Rabbit Monoclonal Antibody

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

UNSPSC Code:
12352203

biological source

rabbit

Quality Level

500

antibody product type

primary antibodies

clone

MRQ-72, monoclonal

packaging

vial of 0.1 mL concentrate (487R-94)
vial of 0.1 mL concentrate (487R-94-RUO) Research Use Only
vial of 0.5 mL concentrate (487R-(95)
vial of 1.0 mL (concentrate (487R-96))
vial of 1.0 mL concentrate (487R-96-RUO) Research Use Only
vial of 1.0 mL pre-dilute (487R-97-RUO) Research Use Only
vial of 1.0 mL pre-dilute ready-to-use (487R-97)
vial of 7.0 mL pre-dilute ready-to-use (487R-98)
vial of 7.0 mL pre-dilute ready-to-use (487R-98-RUO) Research Use Only

manufacturer/tradename

Cell Marque™

isotype

IgG

control

pancreas

visualization

cytoplasmic, nuclear

General description

Mothers Against Decapentaplegic Homolog 4 (SMAD4) is a transcription factor that is involved in TGFβ signalling pathways and acts as a tumor suppressor. SMAD4 is commonly expressed in a variety of cancers, including pancreatic ductal adenocarcinoma (PDA), colorectal carcinoma (CRC), hepatocellular carcinoma (HCC), and gastric carcinomas, as well as non-neoplastic liver, pancreas, and colon. However, a loss of expression has been observed in a subset of PDA, CRC, and gastric carcinomas due to a variety of mutations including nonsense, missense, deletions, and splice site changes. In contrast, SMAD4 is over-expressed in HCC compared to the weak expression that is exhibited in the non-neoplastic liver.

Quality

IVD - MQ500

RUO - MQ100

Physical form

Solution in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide.

Preparation Note

Download the IFU specific to your product lot and format

Note: This requires a keycode which can be found on your packaging or product label.

Other Notes

For Technical Service please contact: 800-665-7284 or email: service@cellmarque.com

Legal Information

Cell Marque is a trademark of Merck KGaA, Darmstadt, Germany

¿No encuentra el producto adecuado?  

Pruebe nuestro Herramienta de selección de productos.

Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

K L Woodford-Richens et al.
Proceedings of the National Academy of Sciences of the United States of America, 98(17), 9719-9723 (2001-08-02)
Loss of chromosome 18q21 is well documented in colorectal cancer, and it has been suggested that this loss targets the DCC, DPC4/SMAD4, and SMAD2 genes. Recently, the importance of SMAD4, a downstream regulator in the TGF-beta signaling pathway, in colorectal
Michael Torbenson et al.
Human pathology, 33(9), 871-876 (2002-10-16)
In the normal liver, the transforming growth factor beta (TGF-beta) signaling pathway plays an important role in inhibiting hepatocyte growth. This effect is mediated through Smad4 (or Dpc4), a tumor-suppressor gene that affects gene transcription and controls cell growth. A
Y H Kim et al.
Annals of oncology : official journal of the European Society for Medical Oncology, 15(4), 574-580 (2004-03-23)
Transforming growth factor-beta (TGF-beta) modulates the growth and function of many cells, including those with malignant transformation. Smad proteins have been identified as major components in the intracellular signaling of TGF-beta family members. To clarify the correlations between clinicopathologic profiles
R Salovaara et al.
Gut, 51(1), 56-59 (2002-06-22)
Loss of DNA sequences from chromosome 18q21 is a major genetic change in colorectal tumorigenesis. Multiple genes have been identified in this area. One of these, DPC4 (deleted in pancreatic cancer 4, also known as SMAD4), is mutated in a
Lauren L Ritterhouse et al.
Histopathology, 75(4), 546-551 (2019-05-06)
SMAD4 (DPC4) is a tumour suppressor gene that is dysregulated in various tumour types, particularly pancreaticobiliary and gastrointestinal carcinomas. Corresponding loss of protein expression has been reported in approximately 50% of pancreatic and 25% of colonic adenocarcinomas. In the evaluation
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico